DESCRIPTION OF EFFECTIVENESS OF CILOSTAZOL AND ASPIRIN AS ADJUVANT OF DIABETIC FOOT WAGNER GRADE II AND III

Pandji Winata Nurikhwan; Zairin Noor; Nelly Al Audhah

doi:10.20527/jbk.v10i12.961

DESCRIPTION OF EFFECTIVENESS OF CILOSTAZOL AND ASPIRIN AS ADJUVANT OF DIABETIC FOOT WAGNER GRADE II AND III

Pandji Winata Nurikhwan, Zairin Noor, Nelly Al Audhah

Abstract

Abstract: Inflammation in patients with diabetic foot will activate platelets and cause aggregation and lead to stasis of blood flow. This inflammation is caused by infection of the diabetic foot. Management of diabetic foot infections in patients is the use of antibiotics. However, the presence of vascularization disorders causing antibiotic delivery to the site of infection to be disrupted so that the process of eradication of infection would be inhibited. One of inflamation markers on patient with diabetic foot is increasing of ESRs.The general objective of this study was to determine the efficacy difference between cilostazol and aspirin as an adjuvant to accelerate tissue healing of diabetic foot care Wagner Grade II – III based on erythrocyte sedimentation rate. This study is a descriptive study using the double-blind and randomized pretest-posttest design. A total of 14 samples is obtained by consecutive sampling. The results showed that four patients given cilostazol showed a 35% reduction in ESR and ten patients were given aspirin showed a 35% reduction in ESR. It can be concluded giving cilostazol and aspirin as adjuvant diabetic foot Wagner II and III showed a decrease in ESR.

Key words: erythrocyte sedimentation rate, diabetic foot, cilostazol, aspirin. Listen

Keywords

erythrocyte sedimentation rate ; diabetic foot ; cilostazol ; aspirin.

Full Text:

PDF

References

Nurul E. Gambaran kasus kaki diabetik dan pengelolaannya pada pasien rawat inap di RS Hasan Sadikin periode 1 Januari 2001-31 Desember 2001. Tesis. Bandung: Universitas Padjadjaran; 2001.

Frykberg RG, Zgonis T, Armstrong DG, et al. Diabetic foot disorders. A clinical practice guideline (2006 revision). J Foot Ankle Surg 2006;45(5 Suppl):S1-66.

Khallaf AN, Fathi O, Ayad W, Fawzy A. Diabetic foot ulcers: conservative management as limb salvage. Egypt, J. Plast. Reconstr. Surgery 2006;30(2):107-111.

La Fontaine J, Harkless LB, Davis CE, et al. Current concepts in diabetic microvascular dysfunction. J Am Podiatr Med Assoc 2006;96(3):245-52.

Ahn CW, Lee HC, Park SW, et al. Decrease in carotid intima media thickness after 1 year of cilostazol treatment in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2001;52(1):45-53.

Mendes JJ, Neves J. Diabetic foot infection: current diagnosis and treatment. The Journal of Diabetic Foot Complications, 2012;4(2):26-45.

Frykberg RG, Zgonis T, Armstrong DG, Driver VR, Giurini JM, Kravitz SR, et al. Diabetic foot disorders a clinical practice guidelne (2006 revision). J Foot Ankle Surg. 2006; 45:S1-66.

Sumpio BE, Lee T, Blume PA. Vascular evaluation and arterial reconstruction of the diabetic foot. Clin Podiatr Med Surg. 2003; 20(4):689-708.

Blann AD, Landray MJ, Lip GYH. 2003. ABC of antithrombotic therapy: An overwiew of antithrombotic therapy. BMJ. 2002; 325:10-13

Reilly M, Mohler E. Cilostazol: treatment of intermittent claudication. Ann Pharmacother 2001;35:48-56.

Katzung, B.G. Basic and Clinical Pharmacology 9th edition. USA : Mc Graw Hill, 2005.

Guo S, DiPietro LA. Factors affecting wound healing. J Dent Res 2010; 89(3): 219-229.

McPherson RA, Pincus MR. Hematology, coagulation, and transfusion medicine. Dalam: McPherson RA, eds. Henry’s clinical diagnosis and management by laboratory method. 22nd ed. Philadelphia: Elsevier Saunders, 2011.

MacKenzie SB, Williams JL. Hematology procedures. Dalam: Williams JL, eds. Clinical laboratory hematology. 2nd ed. New Jersey: Pearson; 2010.

Bain BJ, Bates I, Laffan MA, Lewis SM. Supplementary techniques including blood parasite diagnosis. Dalam: Lewis SM, eds. Dacie & Lewis practical hematology. London: Churchill Livingstone, 2011.

Kumar V., et al. Robbins and Cotran pathologic basis of disease. 8th ed. Philadelphia: Saunders, 2010.

Delves PJ., et al. Roitt’s essential immunology. Massachustes: Blackwell Publishing, 2006.

Farnsworth J, Paulman P. Diabetic foot ulcer and poor compliance. How would you treat ?. The Journal of Family Practice 2005; 54(9):768-76

Kaleta JL, Fleischli JW. Reilly CH. The diagnosis of osteomyelitis indiabetes using erythrocyte sedimentation rate. J Am Podiatr MedAssoc 2001; 91:445– 450.

Greenhagen RM, Johnson AR, Bevilacque NJ. Smoking cessation: the role of the foot and ankle surgeon. Foot ankle Spec 2010; 3(1): 21-8.

Herman H. Efektivitas cilostazol dan plasebo sebagai ajuvan kaki diabetik Wagner II dan III di RSUD Hasan Sadikin. Tesis. Bandung: Fakultas Kedokteran Universitas Padjajaran Bandung, 2012.

Hutagalung HS. Efek aspirin, cilostazol serta clopidogrel terhadap outcomefungsional pada pasien stroke iskemik. Tesis. Medan: Fakultas Kedokteran Universitas Sumatera Utara, 2011.

DOI: http://dx.doi.org/10.20527/jbk.v10i12.961